AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00348595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revlimid
Description: one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
Study NCT01950273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: MabThera, once a week for 4 weeks (4 administrations in total)
Study NCT02611310 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study.
Study NCT03497494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 cm away from the pylorus edge
Description: 2 cm away from the pylorus edge
Study NCT03497494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4 cm away from the pylorus edge
Description: 4 cm away from the pylorus edge
Study NCT03497494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 cm away from the pylorus edge
Description: 6 cm away from the pylorus edge
Study NCT03497494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LRYGB
Description: laparoscopic Roux-en-Y gastric bypass
Study NCT04568356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Direct Antigen Tests for COVID-19
Description: Rapid Antigen diagnostic device performance comparative to RT-PCR
Study NCT03475719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HUG186-B and HUG186-D
Description: Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
Study NCT03475719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUG186
Description: Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
Study NCT00872430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.
Study NCT00872430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Klein Laxative Tea
Description: The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.
Study NCT03229616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT03229616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT03229616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT03229616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT03229616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16)
Description: Etoposide was administered at 15 mg/kg/day on days -3 to -2.
Study NCT02847819 — intervention group
Intervention type: DEVICE
Intervention: airway ultrasound for vocal cords movement assessment.
Description: Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
Study NCT02182583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ba253MDI
Study NCT02182583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ba253BINEB
Study NCT03675308 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for risankizumab administered by subcutaneous injection
Study NCT03675308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for risankizumab administered by subcutaneous injection
Study NCT03675308 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous injection
Study NCT03675308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous injection
Study NCT01517490 — intervention group
Intervention type: OTHER
Intervention: Insulin pump
Description: Insulin pump therapy
Study NCT01517490 — intervention group
Intervention type: OTHER
Intervention: Multiple daily insulin injections
Description: Multiple daily insulin injections
Study NCT01517490 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Pre-operative weight loss and bariatric surgery.
Study NCT00393744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pristinamycin
Description: 50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days
Study NCT00393744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: 50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days
Study NCT01517490 — intervention group
Intervention type: OTHER
Intervention: Medical therapy for type 2 diabetes
Description: Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
Study NCT03930914 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device
Description: Daily use of Parasym (TM) device on tragus or ear lobe, as assigned treatment arm
Study NCT02656745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Smoking Cessation Solution
Description: The intervention regimen is almost entirely user-directed; users will download the application on their iPhones \& engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program.
Study NCT03338205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 1 mg/kg ketamine bolus IV
Study NCT03915080 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oktokog alpha
Description: adjusting dose and dose interval according to MyPKFIT
Study NCT03698617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
Study NCT03698617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For induction of general anesthesia
Study NCT02880969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: answering questionnaires
Study NCT02096809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One week loading of Bone Anchored Hearing Aid (BAHA)
Description: Patients in this arm will be fitted with the BAHA one week after surgery.
Study NCT02096809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Baha BI300/BA400 Implant System
Study NCT02868619 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI
Description: functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
Study NCT02868619 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ADO-BEDS scale
Description: Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
Study NCT04017429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement with osteoplasty
Description: Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to >90 degrees relative to the apico-coronal axis of the tooth.
Study NCT04017429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement with osteoplasty
Description: Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to >90 degrees relative to the apico-coronal axis of the tooth.
Study NCT04017429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement without osteoplasty
Description: Treatment of furcation grade III defect with open flap debridement only.
Study NCT04017429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement without osteoplasty
Description: Treatment of furcation grade III defect with open flap debridement only.
Study NCT03232320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: Meditoxin (Botulinum toxin type A)
Study NCT03232320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Normal saline)
Study NCT00710684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-742457 15mg
Description: SB-742457 - 15mg added to existing donepezil treatment
Study NCT00710684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-742457 35mg
Description: SB-742457 - 35mg added to existing donepezil
Study NCT00710684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo added to existing donepezil
Study NCT00710684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: donepezil 5-10mg
Description: existing donepezil treatment
Study NCT00710684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil 5-10mg
Description: existing donepezil treatment
Study NCT02620241 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sitting position
Study NCT04443621 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: Questionnaire battery for assessment of dignity, cognition, self-sufficiency, and depression.
Study NCT04443621 — intervention group
Intervention type: BEHAVIORAL
Intervention: in-depth interview
Description: Individual in-depth interviews with OAwD on the topic of dignity (two interviews with each respondent at a 12-month interval) .
Study NCT01479686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iMRI
Description: 3.0TiMRI guided resection in adults with glioma
Study NCT01479686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional neuronavigation
Description: conventional neuronavigation guided resection in adults with glioma
Study NCT03765762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRF6019
Description: GRF6019 for IV infusion
Study NCT03765762 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for IV infusion
Study NCT00255658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00255658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00255658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03043222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift as artifical device for prostatic urethral lift.
Description: UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.
Study NCT03043222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroLift as artifical device for prostatic urethral lift.
Description: UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.
Study NCT03043222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embospheres Microspheres as embolic agents for prostate artery embolization
Description: Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
Study NCT03043222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embospheres Microspheres as embolic agents for prostate artery embolization
Description: Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
Study NCT01077362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: SC injections
Study NCT01077362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab 45 mg
Description: SC injections
Study NCT02868619 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: R-CMAS scale
Description: Evaluate the anxiety
Study NCT01077362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab 90 mg
Description: SC injections
Study NCT04758221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment by composite coronal build-up
Description: A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
Study NCT03307915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Participants will receive Ad26.Mos4.HIV 5\*10\^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.
Study NCT03307915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-Mosaic
Description: Participants will receive MVA-Mosaic 10\^8 pfu as IM injection at Weeks 24 and 36.
Study NCT03307915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140 + Mosaic gp140
Description: Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg coformulated with Aluminum phosphate adjuvant) OR an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36.
Study NCT03307915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
Study NCT03307915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
Study NCT02077153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Study NCT02077153 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active participation in group setting
Study NCT01755247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Gel Vehicle
Study NCT01755247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% NVN1000 Topical Gel
Study NCT01755247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% NVN1000 Topical Gel and moisturizer
Study NCT03238456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivating Pacifika Against Cigarettes and Tobacco
Description: Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.~The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages.
Study NCT02364505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine mindfulness-based intervention
Description: Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
Study NCT02364505 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education intervention
Description: Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
Study NCT05947708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate Flow Rate
Description: Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.
Study NCT04231747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CC-97540
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.~During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy.~Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection.
Study NCT04620122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training and Music Therapy
Description: Progressive Muscle Relaxation Training and Music Therapy have applied to the participants two sessions for a week during two months.
Study NCT01859221 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation
Description: Stereotactic radiation
Study NCT03292198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20-30 mmHg compression sleeve and gauntlet
Description: Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists.
Study NCT03292198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20-30 mmHg compression sleeve and gauntlet
Description: Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists.
Study NCT03292198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual Lymphatic Drainage (MLD) is a gentle skin-stretch massage that stimulates the lymphatic system and assists in creating collateral drainage pathways out of non-intact (damaged) lymphatic territories. MLD is a critical part of Complete Decongestive Therapy (CDT), which is accepted as the international standard of care in the treatment of lymphedema.~The MLD sessions will be performed by 2 Certified Lymphedema Therapists, Megan Klote and Sarah Stolker, both trained through the Norton School of Lymphatic Therapy. The therapists have completed reliability meetings regarding MLD sequencing and techniques.
Study NCT00123617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phase III group-based cardiac rehabilitation
Description: Phase III group-based cardiac rehabilitation
Study NCT02375880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: Administration by intravenous (IV) infusion.